Sort   by:  
 Page size 
UnknownEfficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.
Not available
S-EPMC11480158 | biostudies-literature
UnknownEfficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Not available
S-EPMC10730032 | biostudies-literature
UnknownSubcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.
Not available
S-EPMC6512301 | biostudies-literature
UnknownDabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Not available
S-EPMC5834102 | biostudies-literature
UnknownRandomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
Not available
S-EPMC8808992 | biostudies-literature
UnknownHealth-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Not available
S-EPMC9847563 | biostudies-literature
UnknownEfficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Not available
S-EPMC6768896 | biostudies-literature
UnknownHealth-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.
Not available
S-EPMC12010963 | biostudies-literature
UnknownNeoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Not available
S-EPMC6774816 | biostudies-literature
UnknownFinal Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Not available
S-EPMC8855230 | biostudies-literature
Sort   by:  
 Page size